Zasocitinib is a selective tyrosine kinase 2 (TYK2) inhibitor, representing a targeted approach to immunomodulation. This page compares Zasocitinib to other agents used in inflammatory conditions, including Deucravacitinib (Sotyktu), Apremilast (Otezla), Tofacitinib (Xeljanz), Upadacitinib (Rinvoq), and Icotrokinra (Icotyde). While some comparators offer broader JAK inhibition or PDE4 modulation, Zasocitinib's specific TYK2 targeting may offer a distinct safety and efficacy profile.
Zasocitinib Alternatives: How It Compares to Other Oral Targeted Therapies
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 0/7 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape includes established treatments like Tofacitinib (Xeljanz), approved in 2012, and Apremilast (Otezla), approved in 2014. Zasocitinib is not yet approved; however, several pipeline drugs, including Envudeucitinib, are in Phase 3, potentially 1-2 years behind recent approvals.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| Zasocitinib | TYK2 inhibitor | — | Once daily | Pipeline | 61.3% @ 16 weeks | — |
| Apremilast (Otezla) | PDE4 inhibitor | psoriatic arthritis, plaque psoriasis, oral ulcers associated with Behçet's disease | 30 mg twice daily | 2014 | PASI 75: 33.1% @ 16 weeks | $44k |
| Deucravacitinib (Sotyktu) | TYK2 inhibitor | plaque psoriasis, psoriatic arthritis | 6 mg orally once daily | 2022 | PASI 75: 58.4% @ 16 weeks | $74k |
| Icotrokinra (Icotyde) | IL-23 receptor antagonist | plaque psoriasis | Oral, once daily | 2026 | 50% @ Week 16 | — |
| Tofacitinib (Xeljanz) | JAK inhibitor | Rheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis, +2 more | 5 mg twice daily or 11 mg once daily (extended-release) | Pipeline | — | $80k |
| Upadacitinib (Rinvoq) | JAK inhibitor | Rheumatoid arthritis, Psoriatic arthritis, Atopic dermatitis, +6 more | 45 mg once daily for 8 weeks, then 15 mg or 30 mg once daily | Pipeline | Clinical remission: 34% @ 8 weeks | $73k |
| Envudeucitinib | TYK2 inhibitor | — | 40 mg twice daily | Pipeline | 65% @ 24 weeks | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is PASI 90; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for plaque psoriasis specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
Zasocitinib vs Deucravacitinib (Sotyktu)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06973291) enrolling 606 participants, primary completion 2026-04.
Primary-endpoint values for NCT06973291 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
Zasocitinib vs Apremilast (Otezla)
No head-to-head Phase-3 trial directly compares Zasocitinib with Apremilast.
In separate pivotal trials, Zasocitinib reported 61.3% PASI 90 at 16 weeks (NCT06108544) versus 33.1% PASI 75 at 16 weeks for Apremilast (NCT01194219).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Zasocitinib vs Tofacitinib (Xeljanz)
No head-to-head Phase-3 trial directly compares Zasocitinib with Tofacitinib.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Zasocitinib vs Upadacitinib (Rinvoq)
No head-to-head Phase-3 trial directly compares Zasocitinib with Upadacitinib.
In separate pivotal trials, Zasocitinib reported 61.3% PASI 90 at 16 weeks (NCT06108544) versus 34% Clinical remission at 8 weeks for Upadacitinib (NCT03653026).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Zasocitinib vs Icotrokinra (Icotyde)
No head-to-head Phase-3 trial directly compares Zasocitinib with Icotrokinra.
In separate pivotal trials, Zasocitinib reported 61.3% PASI 90 at 16 weeks (NCT06108544) versus 50% PASI 90 at Week 16 for Icotrokinra (NCT06095115).
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational IL-17 / IL-17-related drugs are currently in active Phase 3 development. Among these, Tofacitinib, sponsored by Pfizer, is a JAK inhibitor, representing a different mechanism of action compared to Zasocitinib. Its lead Phase 3 trial is NCT01877668. Upadacitinib, from AbbVie, also employs a distinct JAK inhibition mechanism, with a key study identified as NCT03104374. In contrast, Envudeucitinib, developed by Alumis Inc, is a TYK2 inhibitor, sharing a similar mechanism of action with Zasocitinib. Its lead trial is designated NCT06586112.
Choosing between Zasocitinib and its alternatives
Zasocitinib, as a TYK2 inhibitor, offers a distinct mechanism of action compared to PDE4 inhibitors like apremilast or JAK inhibitors such as tofacitinib and upadacitinib. This targeted approach may be preferred for patients seeking a specific immunomodulatory pathway. While direct comparative efficacy data against all oral comparators is not detailed here, other TYK2 inhibitors like deucravacitinib have demonstrated significant efficacy, with a PASI 75 response of 58.4% at 16 weeks. The convenience of once-daily oral dosing, if applicable to Zasocitinib, could also be a factor for patient adherence.
Conversely, other oral targeted therapies may be preferred based on their established clinical profiles, safety considerations, or specific patient needs. Apremilast (Otezla), a PDE4 inhibitor, has a longer track record and may be considered for patients with milder disease or those seeking a different mechanism of action, demonstrating a PASI 75 response of 33.1% at 16 weeks. JAK inhibitors like tofacitinib (Xeljanz) and upadacitinib (Rinvoq) offer robust efficacy in various inflammatory conditions, with upadacitinib showing clinical remission in 34% of patients at 8 weeks in a specific indication. Icotrokinra (Icotyde), an IL-23 receptor antagonist, provides a distinct oral option for targeting the IL-23 pathway, achieving a PASI 90 response of 50% at Week 16. Factors such as specific safety profiles, long-term data, and cost considerations also play a significant role in treatment selection.
Ultimately, the choice of therapy is a complex clinical decision that should be made by the prescriber in consultation with the patient, taking into account individual patient characteristics, comorbidities, and treatment goals.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT06973291: Zasocitinib vs Deucravacitinib · A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
zasocitinibzasocitinib alternativesalternativescomparisonplaque psoriasistyk2-plaque-psoriasiszasocitinib vs deucravacitinibzasocitinib vs apremilastzasocitinib vs tofacitinibzasocitinib vs upadacitinibzasocitinib vs envudeucitinib